Citi keeps a Sell rating on Sarepta (SRPT) with an $8 price target following the Q4 report. The sees 2026 as a “reset” year for Elevidys, the analyst tells investors in a research note. Citi continues to believe the downside risks outweigh Sarepta’s upside drivers. Market authorization for Amondys and Vyondys could be at risk following the ESSENCE date while competition from Dyne could challenge Exondys’ utilization, contends the firm.
Claim 30% Off TipRanks
New trading tool for SRPT bullsPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta
- Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside
- Sarepta CEO to retire
- Sarepta Therapeutics Announces Planned CEO Leadership Transition
- Sarepta reports Q4 adjusted EPS ($3.58), consensus (77c)